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A dual hypoxic marker technique for measuring
oxygenation change within individual tumors
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Summary Rodent tumour models have been the 'workhorse' for tumour oxygenation research and for investigating radiobiological hypoxic
fraction. Because of the intertumour heterogeneity of blood flow and related parameters, most studies have pooled information derived from
several different tumours to establish the statistical significance of specific measurements. But it is the oxygenation status of and its
modulation in individual tumours that has important prognostic significance. In that regard, the bioreducible hypoxic marker technique was
tested for its potential to quantify oxygenation changes within individual tumours. f-D-lodinated azomycin galactoside (IAZG) and P-D-
iodinated azomycin xylopyranoside (IAZXP) were each radiolabelled with lodine-125 and iodine-131 for measurements of animal tumour
oxygenation. The tumour-blood (T/B) ratio of marker radioactivity in mice after the renal excretion of unbound marker (at 3 h and longer
times) had been shown to be proportional to radiobiological hypoxic fraction. When markers labelled with both radioisotopes were
administered simultaneously to EMT-6 tumour-bearing scidmice, T/B ratios were found to vary by up to 300% between different tumours, with
an average intratumour variation of only -4%. When the markers were administered 2.5-3.0 h apart, changes in T/B ratios of 8-25% were
observed in 10 out of 28 (36%) tumours. Changes to both higher and lower hypoxic fraction were observed, suggestive of acute or cycling
hypoxia. When 0.8 mg g-1 nicotinamide plus carbogen was administered to increase tumour oxygenation, reductions in T/B ratios (mean AT/B
-38%) were observed in all tumours. Similar results were obtained with Dunning rat prostate carcinomas growing in Fischer X Copenhagen
rats whose T/B ratios of IAZG and radiobiological hypoxic fractions are significantly lower. These studies suggest that fluctuating hypoxia can
account for at least 25% of the total hypoxic fraction in some tumours and that correlations between bioreducible marker avidity and related
tumour properties will be optimal when the independent assays are performed over the same time period. This dual hypoxic markertechnique
should prove useful for investigating both spontaneous and induced oxygenation changes within individual rodent tumours.
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The oxygenation status of solid human tumours is one of several
factors known to modulate their response to radiotherapy and ulti-
mate tumour cure. Hypoxic cells are 2.5-3.0 times more resistant
to killing by ionizing radiation (Gray et al, 1953; Chapman et al,
1974) and can be inaccessible for the delivery of and relatively
resistant to some chemotherapy drugs (Tannock et al, 1981). Their
selective survival, reoxygenation and eventual proliferation can
produce local failure after treatment. Many factors associated with
tumour cells and their interactions with host cells can modulate the
oxygenation status of individual tumours as well as the number of
clonogenic cells that are hypoxic and maximally radioresistant
(Chapman, 1997).
Hypoxic fraction (HF) has traditionally been defined as a
macroscopic tumour property, most commonly determined by the
paired survival curve assay (Van Putten and Kallman, 1968;
Moulder and Rockwell, 1984). This technique measures the clono-
genicity ofcells released from solid tumours that have been irradi-
ated with graded doses in air-breathing and asphyxiated animals.
In fact, this procedure is usually performed with five to ten
tumours per treatment group to produce an average value ofHF; it
has proved to be useful for defining average HF as a function of
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tumour cell histology, implantation site and volume (Moulder and
Rockwell, 1984). The distribution of HF values of individual
tumours around their mean value can vary significantly and may
be indicative of the intertumour heterogeneity of this specific
property. Several different invasive and non-invasive assays of
tumour oxygenation are under development for quantifying this
tumour property before, during and after various therapies (Stone
et al, 1993; Chapman, 1997). In that regard, bioreducible hypoxic
markers have the potential for measuring the proportion of viable
hypoxic cells within individual tumours (Chapman et al, 1981).
Chronic hypoxia in tumours results from the proliferation of
their cells to volumes beyond those that can be adequately
supplied with oxygen delivered through tumour vasculature
(Chapman, 1997). Such tumour growth can lead to cords and
necrosis, which have been observed by conventional histology
(Thomlinson and Gray, 1958). More recently, intratumour pressure
was postulated to produce transient vascular occlusions that would
lead to local and acute areas of intermittent hypoxic cells (Brown,
1979). The presence of cycling hypoxia in rodent tumour models
was elegantly demonstrated by a mismatch assay using two fluo-
rescent and vascular-specific probes (Trotter et al, 1989a and b).
This verification of acute or cycling hypoxia indicates that the HF
of a specific tumour may vary significantly over time.
Two bioreducible hypoxic markers developed for the non-inva-
sive detection of tumour hypoxia using nuclear medicine proce-
dures (Schneider et al, 1997) were used to investigate spontaneous
and induced oxygenation changes within individual rodent
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tumours. Differences in tumour avidity for these markers labelled
with different radioisotopes of iodine and administered before and
after oxygen modulation procedures were suggestive ofchanges in
tumour HF. This technique has produced minimal estimates of the
contribution of acute hypoxia to the HF of some animal tumours
and could find a useful role in other tumour oxygenation research.
MATERIALS AND METHODS
Hypoxic markers
The hypoxic markers used in this study were P-D-iodinated
azomycin galactoside (IAZG) and 1-D-iodinated azomycin xylo-
pyranoside (IAZXP). They were synthesized locally and radiola-
belled using procedures that have been reported previously
(Schneider et al, 1997). The kinetics of their covalent linkage to
molecules within tumour cells in vitro and mouse tumours in vivo
have also been reported (Chapman et al, 1996; Schneider et al,
1997). Of the several iodinated azomycin nucleosides tested as
hypoxic markers to date, IAZG and IAZXP have exhibited the
optimal properties (Chapman et al, 1996). In the current study,
IAZG and IAZXP were each radiolabelled with iodine-125 and
iodine-131 to specific activities of 5-10 GBq mmol-'. Each
measurement of hypoxia in mouse and rat tumours was made with
50-80 kBq and 500-800 kBq, respectively, ofradiolabelled markers
at a maximum concentration within animal tissues of0.5-0.7 tM.
Animal tumour models
EMT-6 tumours (Rockwell et al, 1972) were grown in C.B17/Icr
scid mice bred at the Fox Chase Cancer Center. EMT-6 cells
growing in culture flasks were trypsinized, washed in sterile
physiological saline [phosphate-buffered saline (PBS)], concen-
trated by centrifugation and resuspended at 2-5 x 106 cells ml-' in
PBS. Aliquots (0.02 ml) ofcell suspensions were injected subcuta-
neously on the upper backs ofmice. This procedure produced solid
tumours of 0.2-0.5 g at about 10 days after implantation
(Chapman et al, 1996). Hypoxic marker measurements of tumour
oxygenation were performed with tumours whose weights were
usually between 0.2-0.8 g and whose HFs did not vary widely
from a mean value of 35-40%.
The HFs of Dunning rat prostate carcinomas (R3327-AT and
R3327-H) growing in Fischer x Copenhagen rats were also inves-
tigated. Host animals were bred at the Fox Chase Cancer Center.
Tissue from a donor tumour was dissected into fragments of
-10 mm3 in sterile PBS. Under mild anaesthesia with metophane,
a skin area on the back ofeach rat was shaved, sterilized with 95%
alcohol and incised to create a slit of -1 cm length. One tumour
fragment was inserted subcutaneously through the slit, which was
then closed with a metal clip. Tumour growth was monitored twice
weekly until tumours reached volumes of 5-10 cm3 as determined
from three mutually perpendicular measurements of tumour diam-
eter made with callipers (Thorndyke et al, 1985). Previous studies
(Thorndyke et al, 1985; Chapman et al, 1991; Moore et al, 1992,
1993) had shown R3327-AT tumours to exhibit both inter- and
intratumour heterogeneity of blood flow and perfusion with an
average radiobiological HF of -15%. The well-differentiated
R3327-H tumour showed no evidence of significant HF by radio-
biological and hypoxic marker assays (Thorndyke et al, 1985). All
animal tumour procedures were reviewed and approved by our
local Animal Care and Use Committee.
Measurement of tumour avidity for hypoxic marker
The partition coefficients (octanol-water) ofIAZG and IAZXP are
close to 1.0, which facilitated their rapid and relatively equal
distribution to all animal tissues (Schneider et al, 1997). Excretion
of radiolabelled markers from these mice and rats was biphasic.
Over 95% ofthe marker was excreted renally with blood half-lives
of about -0.5 and -1 h for mice and rats, respectively, after which
time a much slower phase of hepatobiliary excretion of metabo-
lized drug was observed. Previous studies had shown that maximal
tumour-blood (T/B) levels of IAZG after its renal excretion phase
(at 3 h and longer) were indicative of hypoxia in EMT-6 tumours
as measured by radioresistance (Chapman et al, 1996). In our
current study, reductions in T/B ratios of a marker labelled with
different isotopes were interpreted as being indicative of increases
in tumour oxygenation, whereas increases in T/B ratios of a
marker were indicative of changes to higher HF. To derive quanti-
tative estimates of radiobiological HF from T/B ratios with a
specific marker, a calibration curve must be experimentally gener-
ated for each tumour model.
Radioactivity in samples of blood (B), muscle (M) and tumour
(T) was measured with a Packard Cobra II Gamma Spectrometer
operating in a dual-channel mode. The upper energy channel was
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Figure 1 (A) The %ID g*-' of [131 ]IAZG (open symbols) administered at
time = 0 and [1251]IAZG (closed symbols) administered at time = 3 h in the
blood (O, 0), muscle (E, *) and tumour (A, A) tissues of EMT-6 tumour-
bearing C.B17/lcr scid mice (n = 5). (B) The tumour/blood (triangles) and
tumour/muscle (squares) ratios of specific tissue radioactivity (%ID g*-1) of
[131I]IAZG (open symbols) and [1251]IAZG (closed symbols) at various times
after administration
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energy channel, which exclusively measured Iodine-125, was
adjusted so that spilldown counts from iodine-131 were a small
percentage of the total. Radioactivity from each isotope obtained
as d.p.m. were back-corrected for decay, corrected for counting
efficiency and converted to per cent injected dose per gram of
tissue (%ID g-'). As the body weights of the animals varied
slightly, the tissue-specific activities for each mouse were adjusted
to a standard mouse (20 g*) using the factor mouse weight/20. T/B
and T/M ratios were calculated from such values of normalized
tissue specific activity (%ID g*-').
Tumour oxygen modulation
Markers labelled with iodine-125 and iodine-131 were adminis-
tered simultaneously to some tumour-bearing animals and 2.5-
3.0 h apart to others. Tumour oxygenation was modulated by
administration of 0.8 mg g-' nicotinamide plus carbogen, which
had been shown to significantly reduce the hypoxic fractions in
some rodent tumours (Horsman et al, 1988, 1990; Chaplin et al,
1991). Nicotinamide was purchased from Sigma, prepared in
sterile PBS at 160 mg ml' and administered i.p. to a final concen-
tration of 0.8 mg g-'. Carbogen gas was purchased as a mixture
from BOC gases and flowed at 31 min-' through sealed cages.
Tumour-bearing animals were placed in these cages and breathed
carbogen at 1 atmospheric pressure throughout the second marker
procedure.
Statistical evaluations
T/B ratios of the markers administered at different times were
subtracted to indicate absolute and percentage changes in HF.
Significance ofchanges in mean value of T/B ratio between groups
ofanimals was analysed using Student's t-test or the Mann-Whitney
test. Variations in T/B ratios observed within groups of similarly
treated animals are reported as standard errors ofthe mean (s.e.m.).
RESULTS
The biodistribution and pharmacokinetics of single administrations
of IAZG and IAZXP to EMT-6 tumour-bearing scid mice have
been reported previously (Chapman et al, 1996; Schneider et al,
1997). Additional studies were performed to determine whether the
pharmacokinetics ofone marker dosage were altered by administra-
tion of the same marker at a different time. Figure IA shows the
%ID g*-' of ['3']IAZG and ['211]IAZG in blood, muscle and tumour
tissues at various times after their administration 3 h apart to the
same groups ofEMT-6 tumour-bearing mice. The open symbols are
specific radioactivities of the first administered marker (1-131),
while the solid symbols are the specific radioactivities of the
second marker (1-125) in the same tissues. Thirty minutes after the
administration of each marker, all the sampled tissues contained
marker at concentrations of 2.2-2.6%ID g*-'. In this experiment,
the rapid clearance rate of IAZG from blood and muscle was char-
acterized by a half-life of -35 min. Extrapolation ofthose data back
to the time of injection yielded initial values of 4-5% ID g*-', a
value close to that expected for the uniform distribution of marker
to the soft tissues ofa 20-g mouse. Selective uptake and retention in
tumour tissue is apparent at 1 h and longer times after administra-
tion. After 3 h, the clearance ofresidual marker is by a much slower
process related to hepatobiliary excretion. Figure lB indicates that
T/B and T/M ratios of marker reached maximum values after the
rapid renal excretion phase of unbound marker. In this study, the
maximal T/B and T/M ratios achieved with IAZG were -11 and
-23 respectively. It is apparent that the pharmacokinetics of [1251]-
IAZG are similar to those of the ['311]IAZG, which was adminis-
tered 3 h earlier. When the tissue levels of the second administered
marker were backshifted by 3 h in Figure IA, the two data sets
were found to superimpose. The symbols represent mean values
from tissue sampled from five tumour-bearing animals at each
timepoint and, in most cases, the s.e.m. was smaller than the size of
the symbols used in both Figures 1A and B. These data give us
confidence that this hypoxic marker can be administered to the
same animals at these concentrations with little or no interference
ofone assay with the other.
Table 1 The oxygenation status of EMT-6 tumours growing in C.B17/lcr
scid mice (n = 12) as measured by the maximal tumour-blood (T/B) ratios of
the hypoxic markers [1251]IAZXP and [131I]IAZXP when administered
simultaneously
Weight (g) T/B (1251) T/B (1311) AT/B % Change
0.17 12.5 13.3 +0.8 6.4
0.18 5.5 5.3 -0.2 3.6
0.20 11.9 11.9 0 0
0.29 10.9 12.0 +1.1 10.1
0.30 9.9 10.4 +0.5 5.0
0.35 13.2 13.1 -0.1 0.8
0.36 12.7 12.8 +0.1 0.8
0.38 13.9 14.1 +0.2 1.4
0.44 10.4 10.3 -0.1 1.0
0.47 10.6 9.8 -0.8 7.5
0.51 11.3 10.9 -0.4 3.5
0.56 11.1 10.2 -0.9 8.1
0.35 0.04a 11.2 0.6 11.2 +0.7 0.4 4.0
aMean + s.e.m.
Table 2 Maximal tumour-blood (T/B) ratios of [1251]IAZXP and [13'I]AZXP
when administered 2.5 h apart for EMT-6 tumours of different size (n = 18).
The asterisks indicate % change in the T/B ratios greater than 8
Weight (g) T/B (1251) T/B (1311) AT/B % Change
0.21 11.3 10.8 -0.5 4.4
0.22 12.0 11.5 -0.5 4.2
0.25 10.2 11.8 +1.6 15.7*
0.25 11.5 11.7 +0.2 1.7
0.26 11.5 11.3 -0.2 1.7
0.38 8.3 7.3 -1.0 12.0*
0.43 9.8 10.0 +0.2 2.0
0.44 10.3 9.8 -0.5 4.9
0.45 11.6 11.2 -0.4 3.4
0.68 9.8 9.3 -0.5 5.1
0.48 13.6 12.6 -1.0 7.4
0.51 11.9 11.2 -0.7 5.9
0.53 12.7 11.7 -1.0 7.9
0.56 11.2 9.6 -1.6 14.3*
0.60 11.0 8.8 -2.2 20.0*
0.65 10.8 11.8 +1.0 9.3*
0.68 9.8 9.3 -0.5 5.1
0.68 12.3 12.3 0 0
0.76 10.3 8.7 -1.5 14.6*
0.46 0.04a 11.1 +0.29 10.6+0.34 0.8 7.5
aMean ± s.e.m.
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Table 3 Maximal tumour/blood (T/B) ratios of [1251]IAZG when administered
3 h before ['3'1]IAZG and tumour oxygen modulation by 0.8 mg g-1
nicotinamide plus carbogen
Weight (g) T/B pre T/B post AT/B % Change
Control
0.27 14.5 14.7 +0.2 1.4
0.28 14.1 14.4 +0.3 2.1
0.31 12.0 14.6 +2.6 21.7*
0.35 11.7 10.8 -0.9 7.7
0.41 11.3 12.1 +0.8 7.1
0.41 13.5 12.6 -0.9 6.7
0.43 13.3 14.6 +1.3 9.8*
0.43 14.2 14.1 -0.1 0.7
0.43 13.3 12.2 -1.1 8.3 *
0.44 13.1 10.4 -2.7 20.6 *
0.38+0.02a 13.1 +0.35 13.1 +0.52 1.1 8.6
Modulated
0.26 15.3 9.9 -5.4 35.3
0.30 16.2 10.1 -6.1 37.7
0.33 15.8 7.8 -8.0 50.6
0.33 18.8 8.9 -9.9 52.7
0.34 13.3 8.2 -5.1 38.3
0.35 16.9 10.0 -6.9 40.8
0.43 14.7 10.2 -4.5 30.6
0.45 17.4 9.9 -7.5 43.1
0.46 15.1 10.7 -4.4 29.1
0.50 16.2 13.5 -2.7 16.7
0.38 + 0.03a 16.0 + 0.48 9.9 + 0.49 6.1 37.5
aMean + s.e.m. Control group (n = 10). Modulated group (n = 10). The
asterisks indicate % change in T/B ratios greater than 8 in control animals.
Table 4 Changes in T/B ratios of radiolabelled IAZG in R3327-AT tumour-
bearing rats before and after modulation with 0.8 mg g-1 nicotinamide and
carbogen gas
Weight (g) T/B Pre T/B Post AT/B % Change
Control
5.6 2.1 2.3 +0.2 9.5
7.4 2.8 3.1 +0.3 10.7
7.7 2.2 2.4 +0.2 9.1
9.6 2.6 2.8 +0.2 7.7
10.2 3.6 3.8 +0.2 5.6
10.8 3.0 3.4 +0.4 13.3
10.9 2.3 2.2 -0.1 4.3
18.7 3.7 4.2 +0.5 13.5
10.1 + 1.39a 2.8 +0.22 3.0 0.26 0.26 9.2
Modulated
8.6 2.9 1.4 -1.5 52
8.9 2.1 1.1 -1.0 48
10.5 2.4 1.6 -0.8 33
11.4 2.2 1.6 -0.6 27
11.5 3.3 0.7 -2.6 79
12.1 3.3 1.6 -1.7 52
13.7 3.4 1.8 -1.6 47
13.9 2.7 2.2 -0.5 19
11.3 +0.69 2.8 0.18 1.5 0.16 1.3 45
aMean ± s.e.m.
Additional preliminary studies were performed to evaluate the
precision of our dual-channel y-scintigraphic procedure. IAZXP
labelled with each iodine isotope was administered i.p. at the same
time to EMT-6 tumour-bearing mice. After 5 h, the animals were
sacrificed and samples from tumour, muscle and blood were
obtained, weighed and analysed for ['311]IAZXP and ['251]IAZXP.
Table 1 shows the tumour weights, the T/B ratios of % ID g*-' for
each marker, the absolute difference in T/B ratio (AT/B) and the
percentage difference in T/B ratios measured by the two markers.
Twelve animals with tumours of 0.17-0.56 g were used in this
investigation. T/B ratios of hypoxic marker varied from 5.3 to
14.1. In spite ofthis large intertumour variation in apparent HF, the
mean value of T/B ratio measured in all the tumours with each
marker was identical (P = 0.923). Each marker clearly delineated
the tumours with the lowest and the highest T/B ratios. When
changes in marker ratios for individual tumours were analysed,
they were found to distribute almost equally to slightly higher and
lower values. The average percentage difference in T/B ratios in
individual tumours measured by the two markers was 4% and less
than 10% for 11 ofthe 12 tumours. These data clearly demonstrate
that the experimental error associated with the measurement ofHF
in individual tumours with two different bioreducible markers is
very small relative to their intertumour variation ofHF. When T/M
ratios were analysed in all the studies, the results followed a
pattern similar to that seen for the T/B ratios, although the actual
numbers were proportionally higher.
The dual hypoxic marker procedure was used to determine
whether or not significant changes in individual tumour HF
occurred over relatively short times. Times of 2.5-3.0 h were
initially investigated, as the data in Figure 1 suggested that little or
no interaction occurred between markers at these times. Tumour-
bearing scid mice were administered 50 kBq of ['251]IAZXP 2.5 h
before the administration of 50 kBq of ['31I]IAZXP. Three hours
after the second marker administration the animals were sacri-
ficed. Blood, muscle and tumour tissues were obtained, weighed
and analysed for specific activities of each marker. Table 2 shows
the tumour weights and values ofT/B ratios of %ID g*-' from two
experiments performed on different days with tumours ofdifferent
volumes. The mean values of T/B ratios of ['251]IAZXP and
['3'I]IAZXP were similar and numerically close to those reported
in Table 1. In 8 of 18 tumours investigated, the difference in T/B
ratios ofmarker was 5% or less, suggestive oflittle or no change in
their HF. We have defined percentage changes of T/B ratios of
markers in individual tumours of 8% and greater (at least two
times the average change reported in Table 1) to be indicative of
significant change in tumour HF. By this criterion, 6 of the 18
tumours reported in Table 2 and four of the ten control tumours
(similarly treated) in Table 3 had different HF at these different
times. These tumours are indicated by asterisks (*) in the tables. It
is reasonable to suggest that these changes result from cycling
hypoxia mechanisms, as almost equal changes to higher and lower
HF were observed.
The dual hypoxic marker technique was also used to investigate
induced oxygenation change within individual tumours in animals
treated with 0.8 mg g-' nicotinamide plus carbogen. Twenty scid
mice with EMT-6 tumours were randomized to two treatment
groups of ten animals each. For this study, [1251]IAZG and
['311]IAZG were used because ofavailability. This hypoxic marker
produces slightly higher maximum values of T/B ratios than does
IAZXP (Chapman et al, 1996). Control animals were administered
50 kBq of ['251]IAZG 3 h before the administration of 50 kBq of
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Table 5 Changes in T/B ratios of radiolabelled IAZG in R3327-H tumour-
bearing rats before and after modulation with 0.8 mg g-1 nicotinamide and
carbogen
Weight (g) T/B Pre T/B Post AT/B % Change
Control
6.5 1.4 1.7 +0.3 21
8 1 0.9 -0.1 10
8.7 1 0.7 -0.3 30
8.9 0.8 0.8 0 0
8.9 0.9 0.8 -0.1 11
9.9 0.9 0.7 -0.2 22
11.6 0.7 0.6 -0.1 14.3
17.9 1.2 1 -0.2 16.7
10.1 + 1.23a 0.99 +0.08 0.90 +0.12 0.16 15.6
Modulated
6.8 1.1 1.2 +0.1 9
7.4 0.8 0.9 +0.1 12.5
7.7 0.8 1.1 +0.3 37.5
9.7 1.6 1 -0.6 37.5
10.7 1.3 0.8 -0.5 38.5
13.9 1 1 0 0
14.5 1.1 1.4 +0.3 27
16.8 1.4 1.2 -0.2 14
10.9+1.32 1.14+0.10 1.08+0.07 0.3 22
aMean + s.e.m.
[13lI]IAZG. Sterile PBS (0.1 ml) was administered i.p. with the
second marker and, 3 h later, animals were sacrificed, tissues were
sampled, weighed and specific activities of markers in tissues
determined. The data for the control animals in Table 3 indicate
that the mean values of tumour HF as measured by T/B ratios of
IAZG were similar at the two times ofobservation (P = 0.937). For
individual tumours, the percentage changes in T/B ratio were less
than 8% in six of ten tumours and greater than 20% in two of ten
tumours. In those tumours that showed an apparent change in HF
(> 8% AT/B), two tumours were to a lower and two were to a
higher HF. In the modulated group of animals, nicotinamide was
administered in 0.1 ml of sterile PBS to a final concentration of
0.8 mg g-' with the second radiolabelled marker and the animals
were placed in a sealed cage with carbogen gas flowing for 1 h.
The data in Table 3 show a significant reduction (average change
of -38%) in T/B ratios of IAZG for this modulated group of
tumours (P < 0.0001). In individual animals, the percentage reduc-
tion in apparent HF ranged from 17% to 53%. These data indicate
that this dual-marker technique has the potential for measuring
oxygenation change within individual rodent tumours.
The dual hypoxic marker technique was further investigated
with Dunning R3327-AT and R3327-H tumours growing in
Fischer x Copenhagen rats. The radiosensitivity, perfusion status
and spontaneous and photodynamic therapy-induced hypoxia in
these tumour models have been reported previously (Thorndyke et
al, 1985; Chapman et al, 1991; Moore et al, 1992, 1993). The
average radiobiological HF of R3327-AT tumours is -15%,
whereas the R3327-H tumour is well perfused with no measurable
HF by the radiobiological or hypoxic marker techniques
(Thorndyke et al, 1985). [1251]IAZG was administered to tumour-
bearing rats at the time of nicotinamide (0.8 mg g-') and carbogen
administration (for 2 h), 5-6 h after an initial administration of
[13'I]IAZG. Each marker was administered at 500-800 kBq and
animals were sacrificed 14-16 h after the second marker adminis-
tration, when T/B and T/M ratios were known to be at maximum
plateau values. The clearance kinetics of these markers from
Fischer x Copenhagen rats requires twice the time ofthe clearance
observed with scid mice. Blood, muscle and tumour tissues were
sampled, weighed and counted to determine the specific tissue
radioactivity of each marker. Table 4 shows results for control
(n = 8) and modulated rats (n = 8) in which R3327-AT tumours of
5-18 g were growing. The largest of these tumours weighed less
than 5% of the rat weight of 400 g, on average. The volumes of
these tumours were at least ten times larger than those ofthe EMT-
6 tumours, but their percentages ofbody weights were similar. The
absolute binding rate of IAZG to hypoxic R3327-AT cells in vitro
is similar to the binding rate to hypoxic EMT-6 cells, when
corrections are made for differences in their cell volumes (JD
Chapman, unpublished data). In spite of this similarity in IAZG
avidity for hypoxic tumour cells in vitro, the T/B ratios of IAZG in
control R3327-AT tumours was -3. This much lower uptake of
IAZG into these tumours in vivo is mainly associated with their
much smaller radiobiological HF. The administration of nicotin-
amide and carbogen to R3327-AT tumour-bearing rats produced a
significant reduction (P = 0.0001) in mean T/B ratio of marker
(average reduction of45%). This proportional change is similar to
that observed with the more hypoxic EMT-6 tumours and varies
from 19% to 79% for individual tumours.
Similar investigations were performed with R3327-H tumour-
bearing rats which exhibit little or no radiobiological hypoxia.
Table 5 shows results from control (n = 8) and modulated (n = 8)
groups of animals. Mean values of T/B ratios of IAZG before
tumour modulation were close to 1.0, which indicates that these
tumours contain few or no zones of hypoxic tumour cells. The
mean values of T/B ratios measured with the two markers in the
control group did not change significantly (P = 0.234). In both
control and modulated tumours, T/B ratios of IAZG increased in
five, decreased in nine and remained the same in two tumours.
While the absolute differences in T/B ratios measured with the two
markers are small, the same changes expressed as a percentage of
the first measurement are relatively large because of the small
denominator. There was no significant reduction (P = 0.612) in
average T/B ratios ofhypoxic marker induced by the nicotinamide
and carbogen treatment. These data confirm that the intrinsic
oxygenation status ofR3327-H tumours is significantly better than
that of R3327-AT tumours and that the reoxygenation effect
induced by nicotinamide and carbogen in R3327-AT tumours was
not measurable in R3327-H tumours.
DISCUSSION
IAZG and IAZXP were chosen for this study because of their
similar binding properties to viable hypoxic cells and their rapid
plasma clearance half-lives (Chapman et al, 1996; Schneider et al,
1997). In addition, both could be readily radiolabelled with
iodine-125 or iodine-131. Both markers rapidly distributed quite
uniformly to all tissues after i.p. injection, achieved maximal
tissue levels within 20-30 min and exhibited clearance half-lives
of about 30 min in mice (Chapman et al, 1996). The initial clear-
ance phase of unmetabolized drug was complete within 3 h. The
binding of marker to hypoxic cells within animal tumours is
dependent upon several pharmacological factors but occurs mainly
over the first hour, when marker concentration is high, and
becomes most evident after the clearance of unbound marker from
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the surrounding normal tissues. This bioreducible hypoxic marker
procedure will have its highest sensitivity for measuring tumour
HF after the initial clearance phase of unbound marker, when T/B
and T/M ratios are maximum. It was at this time that T/B ratios of
IAZG were shown to correlate with tumour radioresistance
(Chapman et al, 1996).
For bioreducible hypoxic markers labelled with different
radioisotopes to detect oxygenation change in individual tumours,
several specific criteria had to be met. As this procedure is
strongly dependent upon the biodistribution and pharmacokinetics
of the marking agent, it was important to demonstrate that two
dosages of the same marker labelled with different radioisotopes
separated in time by a few hours did not interfere with their inde-
pendent pharmacokinetics. The data presented in Figure 1 demon-
strate that when [25I]IAZG and ['311]IAZG were administered 3 h
apart to the same EMT-6 tumour-bearing animals, they showed
little or no interaction. This result was expected as the maximum
concentration of IAZG and IAZXP delivered to most mouse
tissues was -1 p1M. If these same markers were administered at
much higher concentrations (0.1 mm or greater) and/or at closer
times, the probability of one dose affecting a second dose could
be greater. The high specific activities of the radiolabelled
markers used in this study produced a high sensitivity at these low
concentrations.
The intrinsic precision of our dual-channel y-counting proce-
dure was determined with IAZXP labelled with the two
radioisotopes of iodine administered simultaneously to EMT-6
tumour-bearing mice. The average percentage difference in T/B
ratios of %ID g-" of IAZXP was 4% (range from 0 to 10.1%).
This represents the sum of errors associated with marker adminis-
tration to animals, tissue necropsy, tissue weighing as well as the
quantification of radioactivity decays from both iodine-125 and
iodine-131 in the same samples. The data in Table 1 indicate a
remarkably good consistency for predicting tumour HF from
maximal T/B ratios with this hypoxic marker technique. Based
upon these data, we suggested that changes in T/B ratios of
hypoxic marker of 8% and greater (. two times average variation)
in these tumours would indicate significant changes in tumour HF.
According to this criterion, 10 of the 28 control and unmodulated
tumours in Tables 2 and 3 demonstrated significant change in
hypoxic fraction over 2.5-3.0 h. These are indicated by asterisks
(*) in the tables. The average change in T/B ratio for these ten
tumours was -l15% with four shifting to higher HF and six shifting
to lower HF. This result suggests that acute or cycling hypoxia
may account for at least 22% of the HF of some ENIT-6 tumours.
This appears to be a minor component of their total HF, but it
would be incorrect to assume that the remaining HF results from
only chronic mechanisms. On the other hand, bioreducible
markers will be taken up maximally into viable tumour cells that
reside at very low oxygen concentration for the duration of the
marking procedure (1-2 h). Consequently, this technique is biased
towards the labelling of chronically hypoxic cells and more than
80% ofthe marker grains in tumour autoradiographs from labelled
misonidazole were associated with cells adjacent to necrosis
(Chapman et al, 1982). While the dual-marker procedure provides
additional evidence for the presence of acute or cycling hypoxia in
some EMT-6 and R3327-AT tumours, it cannot determine its exact
proportion. These data also showed that tumour HF measured by
the bioreducible marker procedure did not change significantly
over this time in two out of three of the tumours.
When pO, measurements were made in R3327-AT tumours
with the EppendorfpOG microelectrode, 24 h apart, a 60% differ-
ence in median pO, was observed over 24 h (Yeh et al, 1995).
Median pO, was found to increase in nine and decrease in 6 of the
15 tumours used in that study. These electrode measurements
could suggest that the contribution of acute and cycling hypoxia to
HF of R3327-AT tumours is greater than that measured with these
hypoxic markers, although microelectrode measurements were
undoubtedly obtained from tumour tracks that crossed zones of
both viable and dead tumour tissue. Bioreducible markers, on the
other hand, estimate intracellular oxygen levels only in viable cells
whose complement ofreductive enzymes are intact. Consequently,
hypoxic marker avidity to tumour tissue should more closely
correlate with the HF of viable tumour cells. Indeed, when the
ability of different hypoxic assays to predict for tumour radioresis-
tance was investigated in some rodent tumours, tritiated misonida-
zole avidity to tumour best predicted for tumour radioresistance
(Hu et al, 1995; Kavanagh et al, 1996). The proportion of tumour
vessels that stained in murine SCCVII carcinomas by only one
fluorescence probe showed a maximum of -9% for larger tumours
(Trotter et al, 1989a). Although these fluorescent probes elegantly
demonstrated transient blood flow in rodent tumours, they yielded
no information about chronic hypoxia. Consequently, the relative
contribution of acute or cycling hypoxia to total tumour HF could
not be estimated from. those studies. The novel dual-hypoxic
marker experiments described in this manuscript may indicate
minimal estimates of acute relative to total tumour hypoxia.
The sensitivity of this dual-hypoxic marker technique for
measuring oxygenation change induced in individual tumours was
investigated using nicotinamide and carbogen. The concomitant
administration of these agents to tumour-bearing animals has
consistently shown significant reductions in tumour HF (Horsman et
al, 1988, Chaplin et al, 1991). The HFs of EMT-6 and R3327-AT
tumours estimated from T/B ratios of IAZG were consistently and
significantly reduced by the administration of nicotinamide and
carbogen. Although the radiobiological HF and T/B ratios of
hypoxic marker were different for the two tumour models, the
administration of nicotinamide and carbogen gas to tumour-bearing
animals produced an average decrease in T/B hypoxic marker ratios
of 38-45%. These reductions in tumour avidity for hypoxic marker
strongly indicate an increased tumour oxygenation, consistent with
radiobiological estimates ofchanges in tumour HF observed in other
tumour models (Horsman et al, 1990). It should be noted that the
effect of nicotinamide and carbogen on tumours in different animals
was quite variable. Tumour HF appears to be altered by as little as
20% in some tumours and by as much as 80% in others. These data
suggest that the dual-hypoxic marker procedure has the potential for
quantifying induced as well as spontaneous changes in oxygenation
status of individual rodent tumours. Unfortunately, the validation
of such changes of individual tumour HF by specific pharmacolog-
ical procedures will require independent assays performed on
the same tumours. In addition, some tumour-modulating procedures
are known to affect hypoxic marker pharmacokinetics and thus
make comparisons of T/B ratios less informative. But the studies
described in this manuscript clearly show that when different
assays of tumour oxygenation are to be correlated with each other
and with radiobiological HF, the assays should be performed at
the same time. This poses a severe demand for correlations
between different tumour oxygen assays and could prove to be
impossible for some.
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The T/B ratio of IAZG for R3327-H rat prostate carcinomas was
-1.0 for most tumours. This result is indicative of good tumour
oxygenation and consistent with our previous studies that showed
no significant hypoxic fraction by radiobiological or hypoxic
marker procedures (Thorndyke et al, 1985). The administration of
nicotinamide and carbogen to R3327-H tumour-bearing animals
did not significantly change the average T/B ratios of hypoxic
marker. For some R3327-H tumours that exhibited T/B hypoxic
marker ratios greater than 1.3, histological examination ofresected
tumour tissue at autopsy showed zones of only moderate differen-
tiation. This hormone-responsive, well-differentiated rat prostate
carcinoma usually has a latent period after implantation of 3-4
months and a growth doubling time of 12-20 days. The R3327-AT
tumour is an anaplastic variant outgrown from this well-differenti-
ated tumour. From these studies, we have come to learn that
R3327-H tumours, which develop early after implantation, exhibit
faster doubling times or exhibit T/B hypoxic marker ratios of
greater than 1.5, are likely to contain zones of less differentiated
and even anaplastic tumour, some of which can develop zones of
hypoxia.
In summary, the data presented in this manuscript indicate that
bioreducible hypoxic markers labelled with two radioisotopes (or
other distinguishable signals) can be administered at different times
to the same tumour-bearing animals for detection of changes in
tumour oxygenation. T/B or T/M ratios are proportional to tumour
radiobiological HF and changes in marker avidity ratios are consis-
tent with changes in average tumour oxygenation. Of the various
techniques described to date for monitoring tumour oxygenation,
the dual-hypoxic marker procedure may have the greatest use for
measuring average oxygenation change in individual rodent
tumours. This technique has now identified intertumour hetero-
geneity for both spontaneous and induced oxygenation changes in
experimental tumours. Our preliminary experiments suggest that
acute or cycling hypoxia in EMT-6 mouse and R3327-AT rat
tumours can account for, at least, up to 22% of total tumour HF in
some tumours. This result requires validation by independent
assays of tumour hypoxia, but suggests that correlations between
various tumour oxygenation assays and tumour radioresistance
should be performed simultaneously so that differences associated
with changes in tumour HF will be minimized.
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